Transdermal modification of platelet function: An aspirin patch system results in marked suppression of platelet cyclooxygenase

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 559-564

  McAdam, Brendan ^b   Keimowitz, Rudolph M ^b   Maher, Maureen ^b   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN ABSORPTION; THROMBOCYTE AGGREGATION INHIBITION; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADULT; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SKIN; THROMBOXANE B2;

EID: 0030423706     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. Br. Med. J. 308: 81-106, 1994.
2. BUCHANAN, M. R., RISCHKE, J. A., BUTT R., TURPIE, A. G. G , HIRSH, J. AND ROSENFELD, J.: The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thromb. Res. 29: 125-139, 1983.
3. BRONAUGH, R. L., COLLIER, S. W.: In vitro methods for measuring skin permeation. In Skin Permeation Fundamentals, ed. by J. L Zath, pp. 93-111, Allured Publishing Corporation, Wheaton, Illinois, 1993.
4. 2 but not of systemic prostacyclin by controlled release aspirin. N. Engl. J. Med. 3225: 1137-1141, 1991.
5. DEWITT, D. L. AND SMITH, W. L : Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. U.S.A. 85: 1412-1416, 1988.
6. THE DUTCH TIA TRIAL STUDY GROUP. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325: 1261-1266, 1991.
7. 2 J. Pharmacol. Exp. Ther. 259: 1043-1049, 1991.
8. 2 biosynthesis in cardiovascular disease. Circulation 67: 1174-1177, 1983.
9. HAMBERG, M., SVENSSON, J. AND SAMUELSSON, B.: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 72: 2295-2298, 1975.
10. HARTER, H. R., BURCH, J. W., MAJERUS, P. W., STANFORD, N., DEMEZ, J. A., ANDERSON, C. B. AND WERTS, C. A.: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N. Eng. J. Med. 301: 577-579, 1979.
11. 2 reduction versus pregnancy outcome in low-dose aspirin trial. Am. J. Obstet. Gynecol. 173: 578-584, 1995.
12. HLA, T. AND NEILSON, K.: Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 89: 7384-7388, 1992.
13. HUSTED, S. E., PEDERSEN, A. K., PETERSEN, T. AND GEDAY, E.: Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. Eur. J. Clin. Pharmacol. 24: 679-682, 1983.
14. KEIMOWITZ, R. M., PULVERMACHER, G., MAYO, G. AND FITZGERALD, D. J.: Transdermal modification of platelet function: A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 88: 556-561, 1993.
15. LORENZ, R., SIESS, W. AND WEBER, P. C.: Effects of very low versus standard dose acetylsalicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. Eur. J. Pharmacol. 70: 511-518, 1981.
16. MASFERRER, J. L., ZWEIFEL, B. X., MANNING, P. T., HAUSER, S. D., LEAHY, K. M., SMITH, W. G., ISAKSON, P. C. AND SEIBERT, K: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonuclerogenic. Proc. Natl. Acad. Sci. U.S.A. 91: 3228-3232, 1994.
17. MEADE, E. A., SMITH, W. L. AND DEWITT, D. L.: Differential inhibition of prostaglandin endoperoxide synthase (Cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268: 6610-6614, 1993.
18. OBATA, Y., TAKAYAMA, K., MAITANI, Y. AND NAGAI, T.: Effect of pretreatment of skin with cyclic monoterpenes on permeation of diclofenac in hairless rat. Biological and Pharmaceutical Bulletin 16: 312-314, 1993.
19. OKABE, H., TAKAYAMA, K. AND NAGAI, T.: Percutaneous absorption of ketoprofen from acrylic gel patches containing d-limonene and ethanol as absorption enhancers. Chemical and Pharmaceutical Bulletin 40: 1906-1910, 1992.
20. PATRONO, C.: Aspirin as an antiplatelet drug. N. Engl. J. Med. 330: 1287-1294, 1994.
21. PATRIGNANI, P., FILABOZZI, P. AND PATRONO, C.: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69: 1366-72, 1982.
22. PEDERSEN, A. K. AND FITZGERALD, G. A.: Dose-related kinetics of aspirin: Pre-systemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311: 1206-1211, 1984.
23. POTTS, R. O., MCNEILL, S. C., DESDONNET, C. R. AND WAKSHULL, E.: Transdermal drug transport and metabolism II: The role of competing kinetic events. Pharm. Res. 6: 119-124, 1989.
24. PRIBORSKY, J., TAKAYAMA, K., OBATA, Y., PRIBORSKA, Z. AND NAGAI, T.: Influence of limonene and laurocapram on percutaneous absorption of non-steroidal antiinflammatory drugs. Arzneimittel-Forschung 42: 116-119, 1992.
25. REILLY, I. A. G. AND FITZGERALD, G. A.: Inhibition of thromboxane formation in vivo and ex vivo: Implication for therapy with platelet inhibitory drugs. Blood 69: 180, 1987.
26. ROSEKRANZ, B. AND FROLICH, J. C.: Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid. Prostagl. Leuko. Med. 19: 209-300, 1985.
27. SHORR, R. I., RAY, W. A., DAUGHTERY, J. R. AND GRIFFIN M. R.: Concurrent use of nonsteroidal antiiflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med. 153: 1665-1670, 1993.
28. SMITH, W. L.: Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263: F181-F191, 1992.
29. STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321: 129-135, 1989.
30. SVENSSON, J. AND SAMUELSSON, K.: Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease. Thromb. Res. 31: 499-505, 1983.
31. TURPIE, A. G. G., GENT, M., LAUPOIS, A., LATOUR, Y., GUNSTENSEN, J., BASILE, F., KLIMEK, M. AND HIRSH, J.: A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N. Eng. J. Med. 329: 524-529, 1993.
32. WALT, R. P.: Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N. Eng. J. Med. 327: 1575-1580, 1992.
33. WEIL, J., COLIN-JONES, D., LANGMAN, M., LAWSON, D., LOGAN, R., MURPHY, M., RAWLINS, M., VESSEY, M. AND WAJNWRIGHT, P.: Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J. 310: 827-830, 1995.
34. WEKSLER, B. B., KENT, J. L., RUDOLPH, D., SCHERER, P. B AND LEVY, D. E.: Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 16: 5-9, 1985.